Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives

被引:110
|
作者
Solomon, Melani [1 ]
Muro, Silvia [1 ,2 ]
机构
[1] Univ Maryland, Inst Biosci & Biotechnol Res, College Pk, MD 20742 USA
[2] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
Lysosomal enzyme deficiency; Lysosomal storage disorders; Lysosomal diseases; Multi-organ dysfunction; Neurodegeneration; Enzyme replacement therapy; Side effects; Enzyme targeting and delivery; Blood-brain barrier delivery; Enzyme carriers; ICAM-1 mediated enzyme delivery; ALPHA-L-IDURONIDASE; BLOOD-BRAIN-BARRIER; HUMAN ACID SPHINGOMYELINASE; CENTRAL-NERVOUS-SYSTEM; HEMATOPOIETIC STEM-CELL; BETA-HEXOSAMINIDASE-A; MUCOPOLYSACCHARIDOSIS TYPE-VII; HUMAN ARYLSULFATASE-B; MUCOLIPIDOSIS TYPE-IV; GENE-THERAPY;
D O I
10.1016/j.addr.2017.05.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lysosomes and lysosomal enzymes play a central role in numerous cellular processes, including cellular nutrition, recycling, signaling, defense, and cell death. Genetic deficiencies of lysosomal components, most commonly enzymes, are known as "lysosomal storage disorders" or "lysosomal diseases" (LDs) and lead to lysosomal dysfunction. LDs broadly affect peripheral organs and the central nervous system (CNS), debilitating patients and frequently causing fatality. Among other approaches, enzyme replacement therapy (ERT) has advanced to the clinic and represents a beneficial strategy for 8 out of the 50-60 known LDs. However, despite its value, current ERT suffers from several shortcomings, including various side effects, development of "resistance", and suboptimal delivery throughout the body, particularly to the CNS, lowering the therapeutic outcome and precluding the use of this strategy for a majority of LDs. This review offers an overview of the biomedical causes of LDs, their socio-medical relevance, treatment modalities and caveats, experimental alternatives, and future treatment perspectives. (C) 2017 Elsevier By. All rights reserved.
引用
收藏
页码:109 / 134
页数:26
相关论文
共 50 条
  • [1] Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases
    Puhl, Ana C.
    Ekins, Sean
    GEN BIOTECHNOLOGY, 2022, 1 (02): : 156 - 162
  • [2] Enzyme replacement therapies for lysosomal storage disorders
    Germain, DP
    M S-MEDECINE SCIENCES, 2005, 21 : 77 - 83
  • [3] Enzyme replacement therapies in lysosomal storage diseases
    Germain, D. P.
    Boucly, C.
    Carlier, R. Y.
    Caudron, E.
    Charlier, P.
    Colas, F.
    Jabbour, F.
    Martinez, V.
    Mokhtari, S.
    Orlikowski, D.
    Pellegrini, N.
    Perronne, C.
    Prigent, H.
    Rubinsztajn, R.
    Benistan, K.
    REVUE DE MEDECINE INTERNE, 2010, 31 : S279 - S291
  • [4] Enzyme replacement and enhancement therapies for lysosomal diseases
    Desnick, RJ
    JOURNAL OF INHERITED METABOLIC DISEASE, 2004, 27 (03) : 385 - 410
  • [5] Enzyme replacement and enzyme enhancement therapies for lysosomal diseases.
    Desnick, RJ
    MOLECULAR GENETICS AND METABOLISM, 2005, 84 (03) : 197 - 197
  • [6] Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies
    Wanner, C.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (07) : 1234 - 1235
  • [7] Recent advances in enzyme replacement therapies for lysosomal diseases
    Desnick, R. J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 5 - 5
  • [8] Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects
    Herzeg, Akos
    Borges, Beltran
    Lianoglou, Billie R.
    Gonzalez-Velez, Juan
    Canepa, Emma
    Munar, Dane
    Young, Sarah P.
    Bali, Deeksha
    Gelb, Michel H.
    Chakraborty, Pranesh
    Kishnani, Priya S.
    Harmatz, Paul
    Cohen, Jennifer L.
    MacKenzie, Tippi C.
    PRENATAL DIAGNOSIS, 2023, 43 (13) : 1638 - 1649
  • [9] New Therapies for lysosomal Storage Diseases Overcoming the Limits of Enzyme Replacement Therapies
    Muschol, Nicole
    Aries, Charlotte
    PADIATRIE UND PADOLOGIE, 2021, 56 (05): : 217 - 223
  • [10] Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies - Response
    Lidove, Olivier
    Joly, Dominique
    Papo, Thomas
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (07) : 1235 - 1235